April 17, 2012
Actelion Pharmaceuticals Japan announced on April 2 that it received marketing approval from the Ministry of Health, Labor and Welfare (MHLW) on March 30 for Brazaves (miglustat) for the treatment of Niemann-Pick type C disease (NPC). Actelion plans to launch...read more